

Anti-CD19/CD3 ϵ (Blinatumomab), Bispecific Antibody

09/20

CATALOG NO.: A2225-100 (100 μ g)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a bispecific T-cell engager monoclonal antibody that targets both CD19 and CD3 ϵ . A single molecule of this antibody possesses two binding sites: one for CD3 ϵ expressed on T-cells and second for CD19 expressed on B-cells. The antibody forms a synapse between T-cells and malignant B-cells. Upon interaction, T-cells are activated, which release cytotoxic granules such as perforins and granzymes. Granzymes enter the cell cytoplasm with the help of perforins and initiate cell death via activation of caspases. The original antibody has been approved by the FDA to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in both adults and children.

ALTERNATE NAMES: AMG103, BITE MT-103, MEDI-538, MT103, bscCD19xCD3, MEDI 538, MEDI538, MT 103, B4, CVID3, CD19, T3E, TCRE, IMD18, CD3E

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / (scFv-kappa-heavy)-(scFv-heavy-kappa)

SOURCE: CHO cells

IMMUNOGEN: Human CD19/CD3 ϵ

CAS NUMBER: 853426-35-4

MOLECULAR WEIGHT: 54.1 kDa

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-C5 (Eculizumab), Humanized Antibody (A2138)

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)

Anti-TNFSF11 (Denosumab), Human IgG2 Antibody (A2150)

Anti-CD22 (Inotuzumab Ozogamicin), Humanized Antibody (A2179)

Anti-CD19 (Inebilizumab), Humanized Antibody (A2173)

FOR RESEARCH USE ONLY! Not to be used on humans.